Overview
Early infantile developmental and epileptic encephalopathy (EIDEE), historically known as Ohtahara syndrome or early infantile epileptic encephalopathy with suppression-burst, is a severe neurological disorder characterized by the onset of intractable seizures within the first few months of life. It is one of the most severe forms of epilepsy, typically presenting with tonic spasms that may occur in clusters, along with a characteristic suppression-burst pattern on electroencephalography (EEG). The condition profoundly affects the central nervous system, leading to severe developmental delay or regression, intellectual disability, and progressive neurological deterioration. Many affected infants may transition to other epileptic syndromes such as West syndrome or Lennox-Gastaut syndrome over time. The causes of early infantile developmental and epileptic encephalopathy are heterogeneous. Structural brain malformations (such as hemimegalencephaly, porencephaly, or cortical dysplasia) and genetic mutations are recognized etiologies. Numerous genes have been implicated, including STXBP1, KCNQ2, SCN2A, ARX, CDKL5, and others, reflecting the broad genetic heterogeneity of this condition. Both de novo dominant mutations and autosomal recessive inheritance patterns have been described depending on the specific genetic cause. Treatment remains largely supportive and symptomatic. Antiseizure medications such as phenobarbital, vigabatrin, and others are used but seizures are frequently refractory to medical therapy. In cases with identifiable structural lesions, epilepsy surgery may be considered. Adrenocorticotropic hormone (ACTH) or ketogenic diet may be tried in some patients. Despite treatment, the prognosis is generally poor, with significant morbidity and mortality. Many children experience profound neurodevelopmental impairment, and some may not survive beyond early childhood.
Also known as:
Clinical phenotype terms— hover any for plain English:
Variable
Can be inherited in different ways depending on the underlying gene
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for Early infantile developmental and epileptic encephalopathy.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Early infantile developmental and epileptic encephalopathy at this time.
New trials open frequently. Follow this disease to get notified.
Rare Disease Specialist
Rare Disease Specialist
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Early infantile developmental and epileptic encephalopathy.
Community
No community posts yet. Be the first to share your experience with Early infantile developmental and epileptic encephalopathy.
Start the conversation →Latest news about Early infantile developmental and epileptic encephalopathy
Disease timeline:
New recruiting trial: A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine
A new clinical trial is recruiting patients for Early infantile developmental and epileptic encephalopathy
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Early infantile developmental and epileptic encephalopathy
What is Early infantile developmental and epileptic encephalopathy?
Early infantile developmental and epileptic encephalopathy (EIDEE), historically known as Ohtahara syndrome or early infantile epileptic encephalopathy with suppression-burst, is a severe neurological disorder characterized by the onset of intractable seizures within the first few months of life. It is one of the most severe forms of epilepsy, typically presenting with tonic spasms that may occur in clusters, along with a characteristic suppression-burst pattern on electroencephalography (EEG). The condition profoundly affects the central nervous system, leading to severe developmental delay o
At what age does Early infantile developmental and epileptic encephalopathy typically begin?
Typical onset of Early infantile developmental and epileptic encephalopathy is neonatal. Age of onset can vary across affected individuals.
Which specialists treat Early infantile developmental and epileptic encephalopathy?
19 specialists and care centers treating Early infantile developmental and epileptic encephalopathy are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.